Trials / Active Not Recruiting
Active Not RecruitingNCT04042753
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
Phase II Trial of Nivolumab Plus Ipilimumab in Patients With Aggressive Pituitary Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if nivolumab and ipilimumab are effective treatment for people with pituitary tumors have gotten worse after surgery and radiation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ipilimumab | Ipilimumab 3 mg/kg every 3 weeks, |
| DRUG | Nivolumab | Nivolumab 1 mg/kg every 3 weeks for 4 cycles |
| DRUG | Nivolumab | Following concurrent ipilimumab and nivolumab, patients will receive single agent nivolumab at 480 mg every 4 weeks for 6 cycles (1 cycle=4 weeks) with the option of continuing until disease progression or until the end of the study, whichever occurs first |
Timeline
- Start date
- 2019-07-31
- Primary completion
- 2026-07-01
- Completion
- 2026-07-01
- First posted
- 2019-08-02
- Last updated
- 2025-08-08
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04042753. Inclusion in this directory is not an endorsement.